All In Biotech

Drug Trial Radar · NCT01058707

Dose Escalation Study of MLN0128 in Participants With Advanced Malignancies

A Phase I, Open Label, Dose Escalation Study of Oral Administration of Single Agent INK128 in Subjects With Advanced Malignancies Followed by an Expansion in Subjects With Measurable Disease

Last checked: Nov 20, 2026Latest source record: Apr 1, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

198

Actual

Start

Jan 4, 2010

Primary completion

Feb 7, 2019

Study completion Feb 7, 2019

Sponsor

Lead sponsor
Millennium Pharmaceuticals, Inc.Takeda (TAK)
Sponsor type
Industry
First posted
Jan 29, 2010

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a Phase I, open label, Dose Escalation study of oral administration of single agent MLN0128 in participants with Advanced Malignancies followed by an Expansion Phase in participants with renal cell carcinoma, endometrial cancer or urothelial cancer who have measurable disease.

Conditions

  • Advanced Solid Malignancies

Interventions

  • MLN0128Drug

    MLN0128 capsules

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose Escalation Phase: Maximum Tolerated Dose (MTD)Time frame: Cycle 1 (28 Days)
  2. Dose Escalation Phase: Number of Participants With Dose Limiting Toxicities (DLTs)Time frame: Cycle 1 (28 days)
  3. Number of Participants Experiencing One or More Treatment-Emergent Adverse Events (AEs), Serious Adverse Events (SAEs), AEs Resulting in Discontinuation of MLN0128 and Fatal AEs Within 30 Days of Last Dose of Study DrugTime frame: First dose of study drug through 30 days after the administration of the last dose of study drug (Up to approximately 244 weeks)
  4. Dose Expansion: Objective Response Rate (ORR)Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
  5. Dose Expansion Phase: Duration of Objective ResponseTime frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)
  6. Dose Expansion: Duration of Stable Disease (SD)Time frame: From the first dose of study drug up to disease progression or death (Up to approximately 240 weeks)

Locations

16 sites in 2 countries. Site status is shown where the registry gives one.

  • Site not named

    Scottsdale, Arizona

  • Site not named

    Los Angeles, California

  • Site not named

    Miami, Florida

  • Site not named

    Sarasota, Florida

  • Site not named

    Indianapolis, Indiana

  • Site not named

    Boston, Massachusetts

  • Site not named

    Ann Arbor, Michigan

  • Site not named

    Detroit, Michigan

  • Site not named

    Buffalo, New York

  • Site not named

    New York, New York

  • Site not named

    Cleveland, Ohio

  • Site not named

    Oklahoma City, Oklahoma

  • Site not named

    Philadelphia, Pennsylvania

  • Site not named

    Nashville, Tennessee

  • Site not named

    Barcelona, Spain

  • Site not named

    Valencia, Spain

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.